Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Homozygous Familial Hypercholesterolemia
NCT03156621 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Homozygous Familial Hypercholesterolemia
- Lead sponsor
- Regeneron Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 3, 2017
- Completion date
- February 13, 2020
- Enrollment
- 69 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.